Genome Project Spawns New Research On Ethics

With human genetics, it seems, a little knowledge can be a dangerous thing. As the science of genetic diagnosis matures, researchers are learning how to spot dozens of hereditary weaknesses and diseases by simply testing a cheek scraping or a sample of blood. But treating or preventing most of those genetic conditions is still largely the stuff of speculation, and will likely remain so for years. Therein lies an ethical problem, as described by Dorothy Nelkin in her book Dangerous Diagnostics (

Written byChristopher Anderson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

With human genetics, it seems, a little knowledge can be a dangerous thing. As the science of genetic diagnosis matures, researchers are learning how to spot dozens of hereditary weaknesses and diseases by simply testing a cheek scraping or a sample of blood. But treating or preventing most of those genetic conditions is still largely the stuff of speculation, and will likely remain so for years. Therein lies an ethical problem, as described by Dorothy Nelkin in her book Dangerous Diagnostics (The Scientist, Nov. 27, 1989, page 13): Once a person is labeled as genetically flawed, what is to stop the insurance companies, employers, and governments of the world from discriminating against him or her?

As the massive Human Genome Project gets under way, questions of just that sort have prompted the National Institutes of Health to create a new program focusing on the ethical issues that surround the national ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies